Comparative Pharmacology
Head-to-head clinical analysis: POLYCILLIN N versus PROSTAPHLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POLYCILLIN N versus PROSTAPHLIN.
POLYCILLIN-N vs PROSTAPHLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, and activating autolytic enzymes. It is bactericidal against susceptible organisms.
Prostaphlin (oxacillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP1 and PBP3, leading to inhibition of transpeptidation and cell lysis. It is resistant to staphylococcal beta-lactamases.
1-2 g IV/IM every 4-6 hours
250-500 mg IM or IV every 4-6 hours for moderate to severe infections. For oral use: 250-500 mg every 6 hours on empty stomach.
None Documented
None Documented
Terminal elimination half-life: 0.5-1 hour (normal renal function); increases to 7-10 hours in anuria. Prolonged in neonates (2-4 hours).
0.4-0.8 hours in adults with normal renal function; prolonged in renal impairment (up to 4-6 hours in anuria).
Renal: 60-80% unchanged via glomerular filtration and tubular secretion. Biliary: ~20% excreted in bile and feces. Small amount metabolized to penicilloic acid.
Primarily renal (70-80% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic